Evidence synthesis with limited studies

Incorporating genuine prior information about between-study heterogeneity

PSI conference 2018

Dr. Shijie (Kate) Ren, Research Fellow, School of Health and Related Research, University of Sheffield, Sheffield, UK
Motivation

• Evidence can arise from multiple sources in HTA
  o Pairwise meta-analysis (MA), network meta-analysis (NMA)
  o Fixed effect (FE) and random effects (RE) model

• RE model generally preferred
  o Allow for heterogeneity
  o Generalisable beyond included studies

• Problem: limited number of studies
  o National Institution for Health and Care Excellence (NICE) single technology appraisal (STA)
NICE TA163

• Disease: ulcerative colitis
• Outcome measure: colectomy rate at 3 months

No heterogeneity
FE model
0.72 (0.18, 2.70)

High heterogeneity
RE (vague prior)
0.70 (0.01, 84.6)

Variability of treatment effects among studies
Common scenario

NICE STAs

• The company
  o “very few studies…to support the estimation of a random effects model”
  o “instability in the WinBUGS model”
  o “random effects models did not converge”

  Default to the use of a fixed effect model

• The expert review group (ERG)
  o “too few studies…not a valid reason…”
  o “external information should be used…plausible posterior uncertainty”
## Justification of model choice

### NICE STAs (2005-2016)

<table>
<thead>
<tr>
<th>Method (number of submissions)</th>
<th>Justification</th>
<th>N(%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pairwise meta-analysis (38*)</td>
<td>FE model only (7)</td>
<td>No justification</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Check heterogeneity</td>
</tr>
<tr>
<td>Network meta-analysis (71*)</td>
<td>FE model only (24)</td>
<td>Insufficient data</td>
</tr>
<tr>
<td></td>
<td></td>
<td>No justification</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Check heterogeneity</td>
</tr>
</tbody>
</table>

*: Multiple analyses and analyses for multiple outcomes may have been conducted in one submission.

- **Uncertainty: underestimate/overestimate**
- **How to overcome the problem?**
  - Incorporating external evidence
Elicitation framework

- **Aim:** Construct a genuine prior distribution for the heterogeneity parameter using external information
  - Experts’ beliefs

<table>
<thead>
<tr>
<th>TA 163: Colectomy rate at 3 months</th>
<th>OR, median (95% CrI/PrI) infliximab vs. placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>RE model $\tau_{OR} \sim \text{uniform}[0,5]$</td>
<td>$0.70 (0.01, 84.59)$</td>
</tr>
<tr>
<td></td>
<td>$0.69 (0, 2498.82)$</td>
</tr>
</tbody>
</table>

Don’t believe the results (implausible upper limit). RE model should not be used.

So what do you believe could be reasonable?
Technical challenges

How to construct probability distributions for abstract model parameters from judgements about interpretable observable quantities

• Elicit the 'range' of treatment effects
• Transform the prior distribution for the 'range' to obtain the prior for the heterogeneity
Notation

• \( \delta_i \) : treatment effect in study \( i \), for \( i = 1, \ldots, S \)
  o log OR
  o log HR
  o mean difference

• \( \delta_1, \ldots, \delta_S \sim N(d, \tau^2) \)
What quantity to elicit?

- Assume $\delta_i$ is log OR
- Quantity of interest
  - Heterogeneity parameter, $\tau$
- Interpretable observable quantities
  - Study-specific treatment effect, OR
- Propose to elicit: $R = \frac{OR_{97.5}}{OR_{2.5}}$

$\log OR \sim N(d, \tau^2)$
How does it work?

- Make judgements about $R$, then judgements about $\tau$ can be inferred using equation (1)

- Less formal definition of $R$
  - The ratio of the largest to the smallest OR that could arise over a set of studies
  - The ‘range’ of treatment effects
  - TA163: $R = 10$ (The largest OR of having colectomy when comparing infliximab to placebo could not be 10 times more than the smallest OR in a population of studies.)

\[
\delta_{97.5} - \delta_{2.5} = 2 \times 1.96\tau = 3.92\tau \\
\rightarrow \log(R) = 3.92\tau \\
\rightarrow \tau = \frac{\log(R)}{3.92}
\]
What if?

• Expert is only able to specify the best point estimate of $R$
  o No probabilistic distribution

• Expert is not able to say anything about $R$

Three-stage procedure for elicitation
Three-stage procedure

1: Confirm need for RE model

2: Upper bound for the ratio

\[ R_{max} = 10 \]. OR in one study no more than 10 times that of another

3: Full distribution for the ratio

Express some values in \([1, R_{max}]\) as more likely than others

Informative Prior 1
Turner et al. (2012)

Informative Prior 2
Truncated Turner et al. (2012)

Informative Prior 3
Elicited prior
Implementation

- R package: SHELF
- function: `elicitHeterogen()`
- See Ren et al. (2018) for details
• Disease: ulcerative colitis
• Outcome measure: colectomy rate at 3 months
• Fixed effect model was used
• Re-analyse using a random effects with
  o A vague prior U[0, 5]
  o Informative prior 1: Turner et al. (2012)
  o Informative prior 2: Truncated Turner et al. (2012)
  o Informative prior 3: Elicited prior gamma (2.62, 0.721)
## Results

<table>
<thead>
<tr>
<th>Method</th>
<th>OR median (95% CrI) infliximab vs. placebo</th>
<th>OR median (95% CrI) ciclosporin vs. placebo</th>
<th>Probability of heterogeneity</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Low</td>
</tr>
<tr>
<td>FE</td>
<td>0.72 (0.18, 2.70)</td>
<td>0.13 (0.03, 0.44)</td>
<td>0</td>
</tr>
<tr>
<td>RE (vague prior)</td>
<td>0.70 (0.01, 84.59)</td>
<td>0.02 (0, 1.46)</td>
<td>0.01</td>
</tr>
<tr>
<td>RE (Turner prior)</td>
<td>0.71 (0.14, 3.25)</td>
<td>0.11 (0.01, 0.48)</td>
<td>0.11</td>
</tr>
<tr>
<td>RE (Truncated Turner prior)</td>
<td>0.69 (0.17, 2.77)</td>
<td>0.12 (0.03, 0.48)</td>
<td>0.15</td>
</tr>
<tr>
<td>RE (elicited prior)</td>
<td>0.71 (0.17, 2.97)</td>
<td>0.12 (0.03, 0.47)</td>
<td>0.01</td>
</tr>
</tbody>
</table>
Extensions

- Elicitation framework for other types of outcome measures
  - Ordered categorical
  - Continuous
- See Ren et al. (2018) for details
Summary

Evidence synthesis with limited studies

- Use genuine prior distribution for $\tau$
- Minimum requirement: the ratio of the largest to the smallest OR (the ‘range’ of treatment effects)

Variability of treatment effects among studies

- Three-stage elicitation framework using external evidence can help

TRUTH ?

FE

RE (vague prior)
References

• Ren et al. (2018) Incorporating genuine prior information about between-study heterogeneity in random effects pairwise and network meta-analyses. Medical Decision Making 38(4). Open-access.


Thank you.